Live Breaking News & Updates on Company Or Corbus|Page 1

Stay updated with breaking news from Company or corbus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody at the 2023 SITC Annual Meeting

NORWOOD - Corbus Pharmaceuticals Holdings, Inc. , a precision oncology company, today announced that an abstract highlighting pre-clinical data on its CRB-601 anti-aVb8 integrin monoclonal antibody. ....

San Diego , United States , Sean Moran , Company Or Corbus , Exchange Commission , Securities Exchange , Corbus Pharmaceuticals Holdings Inc , Society For Immunotherapy Of Cancer , Pharmaceuticals Holdings , Annual Meeting , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , News Publishing ,

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

NORWOOD, Mass., Sept. 27, 2023 /PRNewswire/ Corbus Pharmaceuticals Holdings, Inc. , a precision oncology company, today announced that an abstract highlighting pre-clinical data on its CRB-601. ....

San Diego , United States , Sean Moran , Ian Hodgson , James Rindone , Rodney Carter , Maneesh Singh , Andrew Kolodziej , Vaishali Shinde , Naomi Muse , Bruce Macklemanaging , Daqing Wang , Securities Exchange , Exchange Commission , Company Or Corbus , Lifesci Advisors , Corbus Pharmaceuticals Holdings Inc , Prnewswire Corbus Pharmaceuticals Holdings Inc , Corbus Pharmaceuticals , Pharmaceuticals Holdings , Annual Meeting , Danish Memon , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Sci Advisors ,

Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

CRB-701 Phase 1 trial in China is ahead of schedule with dose escalation completion expected Q4 2023 and U.S. clinical trial start planned for Q1 . ....

United States , United Kingdom , Sean Moran , Bruce Mackle , Seagen Astellas , Yuval Cohen , Prnewswire Corbus Pharmaceuticals Holdings Inc , American Association Of Cancer Research , Exchange Commission , Drug Administration , Corbus Pharmaceuticals , Lifesci Advisors , Program Updates , Company Or Corbus , Securities Exchange , Corbus Pharmaceuticals Holdings Inc , European Union , Pharmaceuticals Holdings , Chief Executive Officer , Investigational New Drug , European Free Trade Area , American Association , Cancer Research , Quarter Ended June , Looking Statements , Securities Act ,

Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

NORWOOD, Mass., July 31, 2023 /PRNewswire/ Corbus Pharmaceuticals Holdings, Inc. , a precision oncology company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will. ....

United States , Sean Moran , Bruce Macklemanaging , Yuval Cohen , Corbus Pharmaceuticals , Corbus Pharmaceuticals Holdings Inc , Exchange Commission , Securities Exchange , Lifesci Advisors , Company Or Corbus , Corbus Pharmaceuticals Holdings , Chief Executive Officer , Biotechnology Conference , Chat Date , Chat Time , Pharmaceuticals Holdings , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Sci Advisors ,

Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update

Company expands precision oncology pipeline with licensing of CRB-701, clinical-stage Nectin-4 antibody drug conjugate (ADC) from CSPC Pharmaceutical Group
CRB-701 Phase 1 dose escalation ongoing in ....

United States , United Kingdom , Sean Moran , Dennis Riedl , Yuval Cohen , Yong Ben , Lifesci Advisors , Corbus Pharmaceuticals , Corbus Pharmaceuticals Holdings Inc , Exchange Commission , Company Or Corbus , European Union , Securities Exchange , Prnewswire Corbus Pharmaceuticals Holdings Inc , Program Updates , Corbus Board , Pharmaceuticals Holdings , Chief Executive Officer , European Free Trade Area , Chief Operating Officer , Fourth Quarter Ended December , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Sci Advisors , Consolidated Statements ,